| アブストラクト | Aim: Treatment options for triple-class exposed (TCE) patients with multiple myeloma (MM) in Japan are limited. Materials & methods: Retrospective observational study using the Medical Data Vision database (April 2008-April 2021). Eligible adults with MM received a new post-TCE treatment. Treatments, healthcare resource utilization (HCRU) and costs (per patient per month [PPPM]) were analyzed with subgroup analyses by prior stem cell transplantation (SCT vs No SCT). Results: Of 459 TCE patients, 216 (47%) had post-TCE treatment of whom 194 (90%) had no prior SCT. Median duration of the first post-TCE line of therapy (LOT) was 2 months; 49% of No SCT patients received a subsequent LOT. Total healthcare costs were comparable between No SCT and SCT groups ( yen1.3 million PPPM each; US$12,328 and $12,391, respectively), driven by treatment costs. Median post-index overall survival (n = 216) was 15.8 months (95% CI: 10.5, 22.3). Conclusion: New treatments with better effectiveness are needed for patients with TCE MM in Japan. |
|---|
| ジャーナル名 | Future oncology (London, England) |
|---|
| Pubmed追加日 | 2022/11/5 |
|---|
| 投稿者 | Iida, Shinsuke; Nakakoji, Mayuko; Spanopoulos, Dionysis; Okazuka, Kiyoshi; Parulekar, Vipul; Ishida, Tadao |
|---|
| 組織名 | Department of Hematology & Oncology, Nagoya City University Graduate School of;Medical Sciences, Nagoya, Japan.;Bristol-Myers Squibb K.K., Tokyo, Japan.;Bristol-Myers Squibb, Uxbridge, UK.;Mu Sigma, Bengaluru, Karnataka, India.;Department of Hematology, Japanese Red Cross Medical Center, Shibuya, Tokyo,;Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36331578/ |
|---|
